Roberto Odebrecht Rocha

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Nizar M. Tannir, Maria Nirvana Formiga, Konstantin Penkov et al. · Journal of Clinical Oncology · 2024 · 24 citations

Medicine, Immunology, Oncology +17

Impact of the delay to start treatment in patients with lung cancer treated in a densely populated area of Brazil

Fernando Conrado Abrão, Igor Renato Louro Bruno de Abreu, Roberto Odebrecht Rocha et al. · Clinics · 2017 · 22 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Interaction between treatment delivery delay and stage on the mortality from non-small cell lung cancer

Fernando Conrado Abrão, Igor Renato Louro Bruno de Abreu, Roberto Odebrecht Rocha et al. · Journal of Thoracic Disease · 2018 · 17 citations · Full text

Public Health, Biostatistics, Oncology +16

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Roberto Hegg, André Mattar, João Nunes de Matos et al. · Clinics · 2016 · 12 citations · Full text

Medicine, Oncology, Pharmacology +14